PMP22 and myasthenia gravis: The response to IVIg in GBS, MG, and graves ophthalmopathy (GO) could not be attributed to individual B cell-related targets (all of them presented ANN scores below 71%), but complement system-related targets seemed to have a potential individual role (showing at least 71% ANN score; e.g., C5 for all diseases except GO and ITP, and C4B for all diseases as well, except for CIDP, GO, and KD).